Anticoagulation therapy for atrial fibrillation in patients with Alzheimer's disease: A cost-effectiveness analysis

9Citations
Citations of this article
91Readers
Mendeley users who have this article in their library.

Abstract

Background and Purpose-Direct oral anticoagulants (DOACs) are safer, at least equally efficacious, and cost-effective compared to warfarin for stroke prevention in atrial fibrillation (AF) but they remain underused, particularly in demented patients. We estimated the cost-effectiveness of DOACs compared with warfarin in patients with AF and Alzheimer's disease (AD). Methods-We constructed a microsimulation model to estimate the lifetime costs, quality-adjusted life-years (QALYs), and cost-effectiveness of anticoagulation therapy (adjusted-dose warfarin and various DOACs) in 70-year-old patients with AF and AD from a US societal perspective. We stratified patient cohorts based on stage of AD and care setting. Model parameters were estimated from secondary sources. Health benefits were measured in the number of acute health events, life-years, and QALYs gained. We classified alternatives as cost-effective using a willingness-to-pay threshold of $100 000 per QALY gained. Results-For patients with AF and AD, compared with warfarin, DOACs increase costs but also increase QALYs by reducing the risk of stroke. For mild-AD patients living in the community, edoxaban increased lifetime costs by $6603 and increased QALYs by 0.076 compared to warfarin, yielding an incremental cost-effectiveness ratio of $86 882/QALY gained. Even though DOACs increased QALYs compared with warfarin for all patient groups (ranging from 0.019 to 0.085 additional QALYs), no DOAC treatment alternative had an incremental cost-effectiveness ratio

References Powered by Scopus

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

8166Citations
N/AReaders
Get full text

Apixaban versus warfarin in patients with atrial fibrillation

7726Citations
N/AReaders
Get full text

Atrial fibrillation as an independent risk factor for stroke: The framingham study

6341Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review

62Citations
N/AReaders
Get full text

Prevalence of oral anticoagulant use among people with and without Alzheimer’s disease

6Citations
N/AReaders
Get full text

Clinical benefits of oral anticoagulants in atrial fibrillation patients with dementia: a systematic review and meta-analysis

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Vargas, E. R., Sposato, L. A., Lee, S. A. W., Hachinski, V., & Cipriano, L. E. (2018). Anticoagulation therapy for atrial fibrillation in patients with Alzheimer’s disease: A cost-effectiveness analysis. Stroke, 49(12), 2844–2850. https://doi.org/10.1161/STROKEAHA.118.022596

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 20

63%

Researcher 6

19%

Professor / Associate Prof. 4

13%

Lecturer / Post doc 2

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 17

55%

Pharmacology, Toxicology and Pharmaceut... 7

23%

Nursing and Health Professions 4

13%

Social Sciences 3

10%

Save time finding and organizing research with Mendeley

Sign up for free